Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515640 | 1.00 | CTSS (0.48) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL18614278 | 1.00 | CTSS (0.48) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL15240366 | 0.90 | PPARA (0.49) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL1146321 | 0.90 | PPARA (0.49) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL347259 | 0.90 | CTSS (0.48) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL347258 | 0.90 | CTSS (0.48) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL23991234 | 0.87 | CTSS (0.46) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL1360500 | 0.86 | CTSK (0.51) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL66303 | 0.86 | CTSK (0.51) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL66302 | 0.86 | CTSK (0.51) | CTSSCTSKPPARAPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20060223759-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C | 2005-12-01 | — | — | US | disclosed |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | disclosed |
| US-6906056-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2004-06-03 | — | — | US | disclosed |
| EP-1408031-A1 | Pyrolidine derivatives useful in treatment of hepatitis C virus infection | 3 D Gene Pharma (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-6569851-B1 | Treating Alzheimer's disease | ELAN PHARMACEUTIALS, INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1089980-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CTSS 90/4885CTSK 198/4885PPARA 1738/4885 |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CTSS 4198/4885CTSK 4264/4885PPARA 2812/4885 |
| US-20060223759-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | CTSS 1930/4885CTSK 3047/4885PPARA 3435/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | CTSS 2248/4885CTSK 1624/4885PPARA 4063/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CTSS 3101/4885CTSK 2511/4885PPARA 2003/4885 |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CTSS 90/4885CTSK 198/4885PPARA 1738/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CTSS 2248/4885CTSK 1624/4885PPARA 4063/4885 |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CTSS 87/4885CTSK 179/4885PPARA 1886/4885 |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CTSS 90/4885CTSK 198/4885PPARA 1738/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CTSS 4097/4885CTSK 3934/4885PPARA 3369/4885 |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | CTSS 245/4885CTSK 204/4885PPARA 3734/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CTSS 1117/4885CTSK 1920/4885PPARA 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.